Clinical DevelopmentThe acquisition adds a clinical shot on goal with the planned initiation of a Phase IIb study of ALTO-207 in patients with treatment-resistant depression.
Financial StabilityThe company's cash position of $161 million provides financial security until 2028, supporting ongoing and future research efforts.
Research And TrialsALTO-300's mechanism has been linked to specific biomarker signatures, and its safety profile in trials has been favorable, providing confidence in its potential as a precision-guided treatment.